Men who experienced abuse or neglect in childhood show distinct changes in the molecular makeup of their sperm, according to ...

HC Bioscience is shutting down after conducting preclinical models for a transfer RNA (tRNA) asset designed to treat ...

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality worldwide. Current treatment modalities are few or ...

Boston biotech hC Bioscience shuts down after failed hemophilia A program, CEO Leslie Williams says. Company had raised $40M ...

Clinical-stage biotech company aTyr Pharma (ATYR) has seen a significant 24% increase in stock value over the past week, as the company posted ...

Q4 2024 Earnings Call Transcript March 13, 2025 aTyr Pharma, Inc. beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.23. Operator: Good afternoon, ladies and gentlemen, and ...

Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...

圣地亚哥 - 市值约2.99亿美元的临床阶段生物科技公司aTyr Pharma, Inc. (NASDAQ: ATYR )宣布，一项同行评议发表的研究结果支持其主要候选药物efzofitimod在治疗间质性肺疾病（ILD）方面的治疗潜力。根据InvestingPro数据，该公司保持着5.4倍的流动比率，显示出强劲的流动性状况，尽管分析师预计公司在本年度可能面临销售挑战。这项发表在《Science ...

Peer-reviewed publication validates efzofitimod’s unique anti-inflammatory mechanism of action on macrophages through ...

This new article published in Genes & Diseases highlights the critical role of tRNA-derived small RNAs (tsRNAs) in digestive ...